UroGen Pharma Ltd. (URGN)
URGN Stock Price Chart
Explore UroGen Pharma Ltd. interactive price chart. Choose custom timeframes to analyze URGN price movements and trends.
URGN Company Profile
Discover essential business fundamentals and corporate details for UroGen Pharma Ltd. (URGN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 May 2017
Employees
291.00
Website
https://www.urogen.comCEO
Elizabeth Barrett
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
URGN Financial Timeline
Browse a chronological timeline of UroGen Pharma Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.28, while revenue estimate is $62.95m.
Earnings released on 6 May 2026
EPS came in at -$0.47 surpassing the estimated -$0.56 by +16.07%, while revenue for the quarter reached $50.96m , beating expectations by +13.68%.
Earnings released on 2 Mar 2026
EPS came in at -$0.54 falling short of the estimated -$0.52 by -4.25%, while revenue for the quarter reached $37.84m , missing expectations by -5.20%.
Earnings released on 6 Nov 2025
EPS came in at -$0.69 surpassing the estimated -$0.72 by +4.17%, while revenue for the quarter reached $27.48m , missing expectations by -31.53%.
Earnings released on 7 Aug 2025
EPS came in at -$1.05 falling short of the estimated -$0.82 by -28.05%, while revenue for the quarter reached $24.22m , missing expectations by -27.87%.
Earnings released on 12 May 2025
EPS came in at -$0.92 falling short of the estimated -$0.83 by -10.84%, while revenue for the quarter reached $20.25m , missing expectations by -12.93%.
Earnings released on 10 Mar 2025
EPS came in at -$0.80 falling short of the estimated -$0.69 by -15.94%, while revenue for the quarter reached $24.57m , beating expectations by +5.24%.
Earnings released on 6 Nov 2024
EPS came in at -$0.55 surpassing the estimated -$0.84 by +34.52%, while revenue for the quarter reached $25.20m , missing expectations by -3.56%.
Earnings released on 13 Aug 2024
EPS came in at -$0.91 falling short of the estimated -$0.82 by -10.98%, while revenue for the quarter reached $21.85m , missing expectations by -8.81%.
Earnings released on 13 May 2024
EPS came in at -$0.97 falling short of the estimated -$0.93 by -4.30%, while revenue for the quarter reached $18.78m , missing expectations by -12.16%.
Earnings released on 14 Mar 2024
EPS came in at -$0.72 falling short of the estimated -$0.67 by -7.46%, while revenue for the quarter reached $23.53m , beating expectations by +4.25%.
Earnings released on 14 Nov 2023
EPS came in at -$0.68 surpassing the estimated -$0.89 by +23.60%, while revenue for the quarter reached $20.85m , missing expectations by -7.61%.
Earnings released on 10 Aug 2023
EPS came in at -$1.03 surpassing the estimated -$1.13 by +8.85%, while revenue for the quarter reached $21.14m , beating expectations by +5.06%.
Earnings released on 11 May 2023
EPS came in at -$1.30 surpassing the estimated -$1.39 by +6.47%, while revenue for the quarter reached $17.19m , beating expectations by +0.07%.
Earnings released on 16 Mar 2023
EPS came in at -$1.22 falling short of the estimated -$1.12 by -8.93%, while revenue for the quarter reached $18.09m , missing expectations by -2.26%.
Earnings released on 10 Nov 2022
EPS came in at -$1.13 surpassing the estimated -$1.22 by +7.38%, while revenue for the quarter reached $16.10m , missing expectations by -20.10%.
Earnings released on 11 Aug 2022
EPS came in at -$1.18 surpassing the estimated -$1.33 by +11.28%, while revenue for the quarter reached $16.60m , missing expectations by -3.60%.
Earnings released on 10 May 2022
EPS came in at -$1.25 surpassing the estimated -$1.36 by +8.09%, while revenue for the quarter reached $13.56m , missing expectations by -10.60%.
Earnings released on 21 Mar 2022
EPS came in at -$1.27 falling short of the estimated -$1.18 by -7.63%, while revenue for the quarter reached $16.17m , missing expectations by -0.43%.
Earnings released on 15 Nov 2021
EPS came in at -$1.35 falling short of the estimated -$1.26 by -7.14%, while revenue for the quarter reached $11.35m , missing expectations by -26.39%.
Earnings released on 4 Aug 2021
EPS came in at -$1.17 falling short of the estimated -$1.10 by -6.36%, while revenue for the quarter reached $13.03m , meeting expectations.
URGN Stock Performance
Access detailed URGN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
